These medications enhance insulin secretion in response to meals, which can affect energy availability during exercise
PMCID: PMC10341852 Anam M, Maharjan S, et al
The other end-user segment is projected to grow from 4.0% to 6.1% by 2034, as clinical evidence accumulates supporting broader therapeutic applications
Conditions like type 2 diabetes and obesity can increase the risk of digestive issues, including acid reflux and GERD
In June 2024, the FDA officially approved tirzepatide for the treatment of obesity-associated OSAS, marking the first GLP-1based therapy worldwide to receive this indication (16)
As a result of the popularity of Ozempic for weight loss, Novo Nordisk introduced Wegovy